Phathom Pharmaceuticals Inc
PHAT17.660USD
+0.410+2.38%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.25BMarket Cap
LossP/E TTM
More Details of Phathom Pharmaceuticals Inc Company
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Phathom Pharmaceuticals Inc Info
Ticker SymbolPHAT
Company namePhathom Pharmaceuticals Inc
IPO dateOct 25, 2019
CEOBasta (Steven)
Number of employees427
Security typeOrdinary Share
Fiscal year-endOct 25
Address100 Campus Drive
CityFLORHAM PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07932
Phone18777428466
Websitehttps://www.phathompharma.com/
Ticker SymbolPHAT
IPO dateOct 25, 2019
CEOBasta (Steven)
Company Executives of Phathom Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Azmi Nabulsi
Dr. Azmi Nabulsi
Co-Founder, Chief Operating Officer
Co-Founder, Chief Operating Officer
929.34K
-2.52%
Mr. Sanjeev Narula
Mr. Sanjeev Narula
Chief Financial and Business Officer
Chief Financial and Business Officer
144.00K
--
Dr. Asit Parikh, M.D., Ph.D.
Dr. Asit Parikh, M.D., Ph.D.
Independent Director
Independent Director
113.50K
+10.19%
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Independent Director
Independent Director
67.50K
+18.42%
Mr. Michael F. (Mike) Cola
Mr. Michael F. (Mike) Cola
Independent Chairman of the Board
Independent Chairman of the Board
39.80K
+35.84%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
36.01K
--
Mr. Mark Stenhouse
Mr. Mark Stenhouse
Independent Director
Independent Director
30.00K
+53.85%
Mr. Theodore R. (Ted) Schroeder
Mr. Theodore R. (Ted) Schroeder
Independent Director
Independent Director
21.00K
--
Ms. Anne Marie Cook, J.D.
Ms. Anne Marie Cook, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Mr. Steven (Steve) Basta
Mr. Steven (Steve) Basta
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Azmi Nabulsi
Dr. Azmi Nabulsi
Co-Founder, Chief Operating Officer
Co-Founder, Chief Operating Officer
929.34K
-2.52%
Mr. Sanjeev Narula
Mr. Sanjeev Narula
Chief Financial and Business Officer
Chief Financial and Business Officer
144.00K
--
Dr. Asit Parikh, M.D., Ph.D.
Dr. Asit Parikh, M.D., Ph.D.
Independent Director
Independent Director
113.50K
+10.19%
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Independent Director
Independent Director
67.50K
+18.42%
Mr. Michael F. (Mike) Cola
Mr. Michael F. (Mike) Cola
Independent Chairman of the Board
Independent Chairman of the Board
39.80K
+35.84%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
36.01K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
17.14%
Medicxi Ventures (UK) LLP
10.49%
Millennium Management LLC
7.14%
Abingworth Management Limited
4.92%
Invesco Advisers, Inc.
4.54%
Other
55.77%
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
17.14%
Medicxi Ventures (UK) LLP
10.49%
Millennium Management LLC
7.14%
Abingworth Management Limited
4.92%
Invesco Advisers, Inc.
4.54%
Other
55.77%
Shareholder Types
Shareholders
Proportion
Venture Capital
21.47%
Investment Advisor
20.24%
Private Equity
18.18%
Hedge Fund
14.04%
Investment Advisor/Hedge Fund
12.69%
Individual Investor
4.60%
Research Firm
1.13%
Bank and Trust
0.12%
Pension Fund
0.05%
Other
7.49%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
315
60.57M
85.19%
-24.26M
2025Q2
318
61.93M
88.60%
-20.64M
2025Q1
321
68.36M
98.42%
-14.76M
2024Q4
311
70.95M
103.79%
-11.79M
2024Q3
293
76.11M
113.29%
+9.50M
2024Q2
284
61.82M
105.14%
-1.53M
2024Q1
280
58.85M
100.56%
-3.74M
2023Q4
274
57.52M
100.58%
-4.32M
2023Q3
267
60.33M
119.18%
-6.87M
2023Q2
263
58.95M
120.15%
+1.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
12.19M
17.18%
-276.03K
-2.21%
Aug 18, 2025
Medicxi Ventures (UK) LLP
7.46M
10.52%
--
--
Jun 30, 2025
Millennium Management LLC
4.16M
5.86%
+1.91M
+84.87%
Aug 19, 2025
Abingworth Management Limited
3.50M
4.93%
--
--
Aug 28, 2025
Invesco Advisers, Inc.
3.24M
4.57%
-107.39K
-3.20%
Jun 30, 2025
The Vanguard Group, Inc.
2.79M
3.93%
+18.03K
+0.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.00M
4.22%
+86.33K
+2.97%
Jun 30, 2025
Ensign Peak Advisors, Inc.
2.52M
3.55%
+5.69K
+0.23%
Jun 30, 2025
New Enterprise Associates (NEA)
1.96M
2.76%
--
--
Jun 30, 2025
683 Capital Management LLC
2.10M
2.97%
+660.00K
+45.67%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
6.45%
Virtus LifeSci Biotech Products ETF
2.16%
State Street SPDR S&P Pharmaceuticals ETF
1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.35%
Invesco Dorsey Wright Healthcare Momentum ETF
0.92%
Invesco Dorsey Wright SmallCap Momentum ETF
0.53%
iShares U.S. Pharmaceuticals ETF
0.23%
ProShares Ultra Nasdaq Biotechnology
0.13%
iShares Micro-Cap ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.1%
View more
Simplify Propel Opportunities ETF
Proportion6.45%
Virtus LifeSci Biotech Products ETF
Proportion2.16%
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.35%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.92%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.53%
iShares U.S. Pharmaceuticals ETF
Proportion0.23%
ProShares Ultra Nasdaq Biotechnology
Proportion0.13%
iShares Micro-Cap ETF
Proportion0.11%
Invesco Nasdaq Biotechnology ETF
Proportion0.1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Phathom Pharmaceuticals Inc?
The top five shareholders of Phathom Pharmaceuticals Inc are:
Frazier Life Sciences Management, L.P. holds 12.19M shares, accounting for 17.18% of the total shares.
Medicxi Ventures (UK) LLP holds 7.46M shares, accounting for 10.52% of the total shares.
Millennium Management LLC holds 4.16M shares, accounting for 5.86% of the total shares.
Abingworth Management Limited holds 3.50M shares, accounting for 4.93% of the total shares.
Invesco Advisers, Inc. holds 3.24M shares, accounting for 4.57% of the total shares.
Frazier Life Sciences Management, L.P. holds 12.19M shares, accounting for 17.18% of the total shares.
Medicxi Ventures (UK) LLP holds 7.46M shares, accounting for 10.52% of the total shares.
Millennium Management LLC holds 4.16M shares, accounting for 5.86% of the total shares.
Abingworth Management Limited holds 3.50M shares, accounting for 4.93% of the total shares.
Invesco Advisers, Inc. holds 3.24M shares, accounting for 4.57% of the total shares.
What are the top three shareholder types of Phathom Pharmaceuticals Inc?
The top three shareholder types of Phathom Pharmaceuticals Inc are:
Frazier Life Sciences Management, L.P.
Medicxi Ventures (UK) LLP
Millennium Management LLC
Frazier Life Sciences Management, L.P.
Medicxi Ventures (UK) LLP
Millennium Management LLC
How many institutions hold shares of Phathom Pharmaceuticals Inc (PHAT)?
As of 2025Q3, 315 institutions hold shares of Phathom Pharmaceuticals Inc, with a combined market value of approximately 60.57M, accounting for 85.19% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -3.41%.
What is the biggest source of revenue for Phathom Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Phathom Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
